Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Saurabh Saha MD PhD, Chief Executive Officer of Centessa, is scheduled to present at the conference on Wednesday, January 10, 2024, at 4:30 PM PST.
Related news for (CNTA)
- Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
- Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
- Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
